clinical trial · NCT05754957
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Janssen Research & Development, LLC·phase3·completed·n = 14,194
Acute Coronary SyndromeMilvexianPlacebo
brief summary
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).
started
Apr 7, 2023
primary completion
Feb 6, 2026
completion
Feb 6, 2026
last updated
Jun 5, 2026
official title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol